{"filings":[{"id":50446,"accession_number":"0001683168-26-003766","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2026-05-13T12:05:18+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences Q1 2026 net loss down 49% to $0.5M; royalty revenue up 36% to $0.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $0.5M ($0.04 per share) vs $0.9M a year ago; cash $7.3M at March 31, 2026.","Royalty revenue $0.8M (+36% YoY) primarily from Takeda sublicense agreement.","R&D expenses $0.7M (-25% YoY) due to lower preclinical costs; G&A $0.6M, flat.","DNase I platform progress: translational data, manufacturing readiness, Israeli Ministry of Health approval for CAR T study.","Company continuing evaluation of strategic alternatives to maximize shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.2,"consensus_revenue_estimate":null,"consensus_revenue_actual":806923.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":93501,"accession_number":"0001683168-26-003203","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2026-04-24T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Xenetic Biosciences grants 100,000 restricted shares to Interim CEO James Parslow","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Grant of 100,000 restricted shares to James Parslow, Interim CEO and CFO.","7,000 shares vest immediately; 31,000 vest on each of 1st, 2nd, 3rd anniversaries of April 21, 2026.","All unvested shares accelerate upon a Change in Control.","Award is under Amended and Restated Equity Incentive Plan; grant agreement filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105175,"accession_number":"0001683168-26-001744","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2026-03-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences reports 2025 net loss $2.7M, cash $7.9M, advances DNase program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $2.7M for FY2025; royalty revenue from Takeda sublicense rose 19% to $3.0M.","R&D expenses decreased 7% to $3.1M (excl. prior-year impairment); G&A down 20% to $2.7M.","Ended year with $7.9M cash, up $1.7M from prior year-end, aided by $4.0M October public offering.","Preclinical data supporting DNase I for NETs in cancers; progressing toward IND submission.","Pursuing strategic alternatives to maximize shareholder value."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":105174,"accession_number":"0001683168-26-000196","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2026-01-09T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Xenetic Biosciences adjourns 2025 Annual Meeting again; no quorum achieved","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting adjourned from Dec 11, 2025 to Jan 8, 2026 to seek quorum; reconvened but still lacked quorum.","No business conducted on Jan 8, 2026; meeting adjourned again to future date TBD.","Company will provide advance notice of new meeting date and time.","Lack of quorum indicates potential governance/control issues."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121430,"accession_number":"0001683168-25-009076","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2025-12-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xenetic Biosciences adjourns 2025 Annual Meeting to Jan 8, 2026 due to lack of quorum","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Annual Meeting convened Dec 11, 2025 adjourned without business due to insufficient quorum.","Meeting reconvenes Jan 8, 2026 at 10:00 AM ET virtually; record date remains Oct 15, 2025.","Previously submitted proxies remain valid; stockholders who haven't voted urged to vote by Jan 7, 2026.","Definitive proxy statement filed Oct 31, 2025 unchanged; solicitation materials available on SEC website."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121429,"accession_number":"0001683168-25-008288","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences Q3 net loss ~$0.5M, revenue up 67% to $1.0M; cash extended by $3.9M offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of approximately $0.5M for Q3 2025; revenue rose 67% YoY to $1.0M on higher Takeda royalty payments.","R&D expenses increased 105.6% to $0.8M due to manufacturing and pre-clinical work; G&A rose 9.3% to $0.8M on legal costs.","Cash at Sept 30, 2025 was ~$4.1M; subsequent October 2025 offering added ~$3.9M net proceeds, extending runway.","DNase I program advancing toward IND submission and Phase 1 for pancreatic and solid tumors; preclinical studies ongoing.","PeriNess agreement for investigator-initiated studies in Israeli centers under regulatory approval process."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":2210115.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":121428,"accession_number":"0001683168-25-007528","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2025-10-14T23:59:59+00:00","items":["1.01","8.01","9.01"],"status":"ready","headline":"Xenetic Biosciences prices $4.5M underwritten offering of 735,000 shares at $6.12/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 735,000 common shares at $6.12 each for gross proceeds of ~$4.5M; net proceeds ~$3.9M after discounts and expenses.","Expected to close on or about October 14, 2025, subject to customary closing conditions.","Net proceeds to be used for working capital, general corporate purposes, and advancement of DNase technology.","Canaccord Genuity is sole bookrunner; offering made under effective shelf registration statement (File No. 333-282756)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":138090,"accession_number":"0001683168-25-006001","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences Q2 2025 net loss $0.7M; cash $4.8M; expands Scripps partnership","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss ~$0.7M for Q2 2025; no revenue reported.","R&D expenses fell 29.7% to ~$0.7M; G&A down 41.8% to ~$0.7M vs Q2 2024.","Cash at quarter-end ~$4.8M to fund operations.","Expanded collaboration with Scripps Research Institute for DNase I plus CAR T-cell studies.","Partner PeriNess commenced patient dosing in pancreatic cancer study; exploratory CAR T study in large B cell lymphoma."],"consensus_eps_estimate":-0.6528,"consensus_eps_actual":-1.03,"consensus_revenue_estimate":null,"consensus_revenue_actual":1183158.0,"consensus_period":"2025-Q2","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155505,"accession_number":"0001683168-25-003513","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences Q1 2025: net loss $0.9M, revenue $0.6M (+16%), cash $5.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of ~$0.9M for Q1 2025; revenue increased 16.1% to ~$0.6M from $0.5M in Q1 2024.","Total operating costs decreased 13.7% to ~$1.5M, primarily due to lower personnel costs after CEO/CSO departures in mid-2024.","Cash position of $5.2M at quarter end; no guidance or dividend changes.","Advancing DNase I platform; collaboration with PeriNess for exploratory studies in osteosarcoma, Ewing sarcoma, and pancreatic carcinoma."],"consensus_eps_estimate":-0.7344,"consensus_eps_actual":-0.59,"consensus_revenue_estimate":null,"consensus_revenue_actual":593261.0,"consensus_period":"2025-Q1","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":155504,"accession_number":"0001683168-25-002396","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Xenetic Biosciences' auditor Marcum resigns due to acquisition; CBIZ engaged as new auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned as auditor on April 8, 2025, after CBIZ acquired its attest business; Audit Committee approved.","No disagreements or reportable events between company and Marcum during FY2024, FY2023, and through resignation.","CBIZ engaged as new independent auditor on April 9, 2025, for the fiscal year ending December 31, 2025.","Marcum's audit reports for FY2024 and FY2023 were unqualified, with no adverse opinion or modifications.","No prior consultations with CBIZ on accounting or auditing matters."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173991,"accession_number":"0001683168-25-001693","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2025-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences FY2024 net loss $4.0M; cash $6.2M; advancing DNase I to IND","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss ~$4.0M for FY2024; R&D expenses fell 5.9% to $3.3M from $3.5M YoY.","Royalty payments from Takeda sublicense ~$2.5M, relatively flat vs. prior year.","Cash and cash equivalents at year-end ~$6.2M.","Continuing DNase I development toward IND/Phase 1 for pancreatic carcinoma.","Entered Clinical Trial Services Agreement with PeriNess for exploratory studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":173990,"accession_number":"0001683168-25-001712","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K/A","filed_at":"2025-03-19T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Xenetic Biosciences reports FY2024 net loss of ~$4.0M, cash $6.2M, advances DNase program","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2024 ~$4.0M; R&D expenses $3.3M (down 5.9% YoY), G&A $3.4M (down 4.1%).","Royalty payments from Takeda sublicense ~$2.5M, flat YoY; cash balance $6.2M at year-end.","Entered Clinical Trial Services Agreement with PeriNess for DNase I studies in pancreatic, colorectal, and solid tumors.","Extended collaborations with University of Virginia and Scripps Research through 2025.","Progressing DNase I development program toward IND and first-in-human study for pancreatic carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190962,"accession_number":"0001683168-24-008712","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2024-12-13T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xenetic Biosciences reports results of 2024 annual meeting; all proposals pass","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All six director nominees elected; for votes ranged from 458,022 to 486,395; broker non-votes 391,780.","Ratification of Marcum LLP as auditor approved: 878,207 for, 15,137 against, 3,419 abstain.","Advisory say-on-pay compensation approved: 462,285 for, 40,600 against, 2,098 abstain.","Say-on-frequency set to every 1 year: 470,918 for 1 year; 3,600 for 2 years; 3,631 for 3 years."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190961,"accession_number":"0001683168-24-007929","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Q3 net loss $0.4M, R&D down 64% to $0.4M, cash $6.8M; advancing DNase platform toward Phase 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $0.4M for Q3 2024; no material revenue reported.","R&D expenses fell 63.9% YoY to $0.4M from $1.0M due to lower process development spending.","Cash and equivalents were $6.8M at September 30, 2024.","Preclinical data for DNase I combination therapies in colorectal cancer models completed; presented at SITC 2024.","Strategic focus on institutional partnerships with Tokyo Medical University and Scripps Research Institute."],"consensus_eps_estimate":-0.1428,"consensus_eps_actual":-1.89,"consensus_revenue_estimate":null,"consensus_revenue_actual":1851464.0,"consensus_period":"2024-Q3","consensus_source":"xbrl+finnhub","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190960,"accession_number":"0001683168-24-007710","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Xenetic extends Scripps collaboration with $400k funding for DNase platform","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Extended Research Funding & Option Agreement with Scripps Research by 12 months; total funding up to ~$400,000.","Initial $65k payment on Nov 1, 2024, followed by ~$65k monthly payments over 5 months.","Focus: systemic DNase I combined with CAR T-cell therapies for hematological cancers and melanoma.","Xenetic holds option to acquire exclusive license to new IP from the DNase research program.","Advancing DNase oncology platform toward Phase 1 for pancreatic carcinoma and solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":190959,"accession_number":"0001683168-24-007527","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Two Xenetic directors not standing for re-election at 2024 Annual Meeting","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James E. Callaway and Adam Logal will not stand for re-election at the 2024 Annual Meeting of Stockholders.","Neither director's decision related to any disagreement with the Company on operations, policies or practices.","The Company thanked both directors for their dedicated Board service."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":207442,"accession_number":"0001683168-24-005600","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences Q2 net loss $1.3M; cash $7.3M; DNase program advancing","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.3M for Q2 2024; R&D expenses flat at $0.9M; G&A up 19.5% to $1.1M on severance.","Royalty payments from Takeda sublicense of PolyXen platform were $0.7M, up 11.6% YoY.","Cash balance $7.3M at quarter end; expected to fund operations into clinical development.","Preclinical studies for DNase oncology platform ongoing; data expected before year end.","Advancing towards Phase 1 clinical proof-of-concept in pancreatic carcinoma and solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.6,"consensus_revenue_estimate":null,"consensus_revenue_actual":1237221.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224866,"accession_number":"0001683168-24-004415","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2024-06-21T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Xenetic appoints Parslow Interim CEO at $400k salary, $100k retention bonus; separations with former CEO/CSO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["James Parslow appointed Interim CEO effective May 16, 2024; base salary increased to $400,000.","Parslow eligible for $100,000 cash retention bonus if employed for ten months; receives option for 20,000 shares.","Confidential separation agreements with former CEO Jeffrey Eisenberg and former CSO Curtis Lockshin providing severance per existing agreements.","Eisenberg Separation Agreement includes accelerated vesting of all unvested stock options as of May 16, 2024.","Stock option grant vests 1/4 on grant date and 1/4 on each of first three anniversaries, subject to continued employment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224865,"accession_number":"0001683168-24-003779","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Xenetic Biosciences CEO Eisenberg and CSO Lockshin depart; CFO Parslow named interim CEO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jeffrey F. Eisenberg stepped down as CEO and resigned as director effective May 16, 2024.","Dr. Curtis Lockshin stepped down as Chief Scientific Officer, effective May 16, 2024.","James F. Parslow, CFO since April 2017, appointed interim CEO; continues as principal financial officer.","Parslow is a CPA with over 35 years experience; no related-party transactions or family relationships noted.","Company advancing DNase oncology program toward Phase 1; preclinical data expected before year-end."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":224864,"accession_number":"0001683168-24-003192","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2024-05-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences reports Q1 2024 net loss of $1.2M; cash at $7.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of approximately $1.2M for Q1 2024; R&D expenses up 58.6% to $0.9M on DNase preclinical work.","Ended quarter with $7.8M cash; advancing DNase oncology program towards Phase 1 for solid tumors.","Expects multiple preclinical data readouts in H2 2024 to guide clinical development strategy.","G&A expenses decreased 9.8% to $0.8M compared to prior year quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.78,"consensus_revenue_estimate":null,"consensus_revenue_actual":510817.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244132,"accession_number":"0001683168-24-001606","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2024-03-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences reports FY2023 net loss of $4.1M; cash at $9.0M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $4.1M for year ended Dec 31, 2023; R&D expenses down 26.7% to $3.5M.","Royalty payments from Takeda sublicense rose 48.8% to $2.5M in 2023.","Cash and cash equivalents of $9.0M at year-end to fund operations.","Advancing DNase-based oncology platform targeting pancreatic carcinoma toward Phase 1 trial.","Entered research funding and material transfer agreement with University of Virginia."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":244131,"accession_number":"0001683168-24-000866","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2024-02-12T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Xenetic Biosciences posts investor video by CSO on DNase I oncology preclinical data","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Chief Scientific Officer Curis Lockshin, PhD, discusses preclinical data from DNase I oncology platform.","Video available at https://www.virtualinvestorco.com/wtm-xbio-8k.","No financial results, guidance, or material business changes disclosed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261546,"accession_number":"0001683168-23-008731","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2023-12-08T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xenetic Biosciences shareholders reject non-binding say-on-pay proposal at 2023 annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Nine director nominees elected; Dr. Dmitry Genkin received highest 'for' votes (461,413), Jeffrey Eisenberg lowest (255,632).","Ratification of Marcum LLP as auditor approved with 804,522 for, 21,792 against.","Say-on-pay advisory proposal failed: 153,605 for, 318,665 against, 2,112 abstained; received less than one-third of votes cast.","Broker non-votes of 356,015 on director elections and say-on-pay due to routine/non-routine mix."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.15,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":261545,"accession_number":"0001683168-23-007922","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2023-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences reports Q3 net loss of $1.1M; R&D spend up 156% on DNase platform","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $1.1M for Q3 2023; cash at $9.8M.","R&D expenses rose 155.9% to $1.0M on DNase platform preclinical work.","Royalty income from Takeda sublicense up 47.5% to $0.6M.","Advancing DNase platform toward first-in-human study for pancreatic carcinoma.","G&A expenses down 14.6% to $0.7M."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.94,"consensus_revenue_estimate":null,"consensus_revenue_actual":1868023.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":278765,"accession_number":"0001683168-23-005538","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2023-08-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences Q2 net loss $1.1M; expands DNase platform with VolitionRx SOW","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of ~$1.1M for Q2 2023; R&D expenses fell 56.5% to ~$0.9M vs $2.1M in Q2 2022.","Royalty payments from Takeda sublicense were ~$0.7M in Q2 2023, up 56.2% from prior year.","Cash position of ~$10.7M at quarter end; no outstanding debt.","Executed first Collaborator SOW with VolitionRx and CLS for NETs-targeted CAR T cell therapies in solid cancers.","Advancing DNase-based oncology program towards Phase 1 study for pancreatic carcinoma and other solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.25,"consensus_revenue_estimate":null,"consensus_revenue_actual":1256849.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297017,"accession_number":"0001683168-23-003931","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2023-06-06T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xenetic Biosciences furnishes updated corporate presentation for investor meetings","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Presentation dated June 2023; no specific financial or operational updates disclosed in the filing.","Filed under Item 7.01 Regulation FD; presentation is furnished, not filed.","No material new information beyond the existence of the updated presentation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297016,"accession_number":"0001683168-23-003826","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2023-06-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Xenetic Biosciences regains Nasdaq minimum bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on May 30, 2023 confirming compliance with Listing Rule 5550(a)(2).","Compliance achieved after closing bid price >= $1.00 for 10 consecutive days (May 15-26, 2023).","Previous deficiency was notified on June 3, 2022; this matter is now closed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297015,"accession_number":"0001683168-23-003243","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2023-05-12T23:59:59+00:00","items":["3.03","5.03","7.01","9.01"],"status":"ready","headline":"Xenetic Biosciences announces 1-for-10 reverse stock split effective May 15, 2023","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse split reduces outstanding shares from 15,166,596 to ~1,516,660; authorized shares from 100M to 10M.","Effective 12:01 a.m. ET on May 15, 2023; no fractional shares – any fraction rounded up.","Common stock continues trading on Nasdaq under symbol XBIO with new CUSIP 984015602.","Warrants (XBIOW) and equity awards proportionately adjusted; no action required by holders.","Press release issued May 12, 2023; Certificate of Change filed with Nevada Secretary of State."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":297014,"accession_number":"0001683168-23-003203","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2023-05-11T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences Q1 net loss $0.9M; cash $12M; Takeda royalties up 55.7%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of $0.9M for Q1 2023; R&D expenses down 46% to $0.6M from $1.1M.","Royalty payments from Takeda sublicense increased 55.7% to $0.6M.","Ended quarter with $12.0M cash; advancing DNase oncology program.","Entered collaboration with Scripps Research Institute for DNase and CAR T programs.","Appointed Scott N. Cullison and Reid P. Bissonnette to support DNase platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.06,"consensus_revenue_estimate":null,"consensus_revenue_actual":605844.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":317392,"accession_number":"0001683168-23-001681","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2023-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences FY 2022 net loss $6.6M; cash $13.1M; DNase platform advances toward Phase 1","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY 2022 was approximately $6.6 million; R&D expenses rose 50.8% to $4.8M.","Cash at year-end totaled $13.1 million, expected to fund operations and pipeline development.","Royalty payments from Takeda sublicense were ~$1.7M, up 47.1% YoY.","DNase oncology platform progressing towards first-in-human study combined with checkpoint inhibitors or chemo.","Appointed oncology and NETs experts Allan Tsung, MD and Jonathan Spicer, MD, PhD to Scientific Advisory Board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335622,"accession_number":"0001683168-22-008623","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2022-12-22T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xenetic stockholders approve increase in authorized common stock from 50M to 100M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal Four passed: 7,204,486 For, 1,131,034 Against, 110,245 Abstained, no broker non-votes.","Amendment to Articles of Incorporation increases authorized common stock from 50M to 100M shares.","Annual meeting reconvened on Dec. 21, 2022 solely for this proposal after initial adjournment on Dec. 7, 2022.","No other matters were considered or voted upon at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.15,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335621,"accession_number":"0001683168-22-008311","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2022-12-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xenetic Biosciences annual meeting adjourned on share-increase proposal; all directors elected","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Elected all 7 director nominees: Borisenko, Callaway, Dastoor, Eisenberg, Kornberg, Logal, Vinogradov.","Ratified Marcum LLP as independent auditor for FY2022 with 7.37M for, 58K abstained.","Advisory vote on executive compensation approved: 4.23M for, 700K against, 66K abstain.","Proposal 4 (increase authorized shares from 50M to 100M) adjourned to Dec 21; >80% of votes cast but not >50% of outstanding shares."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.15,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335620,"accession_number":"0001683168-22-008170","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2022-12-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Xenetic Biosciences receives Nasdaq extension to May 29, 2023 to regain $1 bid price compliance","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq granted an additional 180 calendar days, until May 29, 2023, to meet the $1.00 minimum bid price requirement.","Company previously notified of non-compliance on June 3, 2022; bid price below $1.00 for 30 consecutive business days.","Eligibility based on meeting all other initial listing standards and written intent to cure via reverse stock split if needed.","If bid price closes at $1.00+ for 10 consecutive days before May 29, 2023, compliance will be achieved.","Failure to cure may lead to delisting, subject to appeal to a Nasdaq hearings panel."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335619,"accession_number":"0001683168-22-007476","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2022-11-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences reports Q3 2022 net loss of $0.8M; cash of $13.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for Q3 2022 was approximately $0.8 million.","R&D expenses fell 48.9% YoY to $0.4 million, reflecting shift from XCART to DNase platform.","G&A expenses decreased 8.7% to $863,000.","Cash and cash equivalents were $13.8 million at quarter-end; expected to fund operations and pipeline development.","DNase oncology platform advancing toward first-in-human study for pancreatic carcinoma."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":1219953.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":335618,"accession_number":"0001683168-22-006850","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2022-10-12T23:59:59+00:00","items":["3.02","9.01"],"status":"ready","headline":"Xenetic Biosciences issues 850,000 shares to CLS Therapeutics for patent rights","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 850,000 common shares to CLS Therapeutics LLC as consideration for assignment of certain patent rights.","Transaction closed on October 12, 2022; shares unregistered and sold under Section 4(a)(2) and Regulation D.","CLS represented itself as an accredited investor; shares restricted and not registered under Securities Act.","No other securities or cash consideration disclosed; shares issued directly for patent asset acquisition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353054,"accession_number":"0001683168-22-005590","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2022-08-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences reports Q2 net loss of $2.7M; advances DNase platform toward Phase 1 study","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss of approx $2.7M for Q2 2022; R&D expense rose 296% to $2.1M, including $1.3M IPR&D for DNase license.","Cash balance of $14.9M at quarter end; royalty payments from Takeda sublicensee ~$0.4M (+45% YoY).","In-licensed DNase-based oncology platform from CLS Therapeutics in April 2022; targeting Phase 1 in pancreatic carcinoma.","Engaged Catalent for cGMP manufacturing of Phase 1 clinical supply; collaboration with Belgian Volition for NETs-targeted cell therapies.","Bolstered IP with U.S. patent for XCART platform covering co-administration of CAR T cells with personalized vaccine."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.31,"consensus_revenue_estimate":null,"consensus_revenue_actual":805703.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":353053,"accession_number":"0001683168-22-004819","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2022-07-07T23:59:59+00:00","items":["1.01","7.01","9.01"],"status":"ready","headline":"Xenetic enters manufacturing agreement with Catalent for DNase clinical supply up to $5M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estimated project cost up to ~$5M for cGMP manufacturing of Human DNase I over ~17 months.","Catalent to provide manufacturing services for clinical supply to support planned Phase 1 study.","DNase platform targets NETs to enhance efficacy of immunotherapies and chemotherapies in solid tumors.","Initial indication focus includes pancreatic carcinoma, a multi-billion-dollar market.","CEO Jeffrey Eisenberg says this is an important step towards first-in-human studies."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370702,"accession_number":"0001683168-22-004180","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2022-06-06T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Xenetic Biosciences receives Nasdaq minimum bid price deficiency notice","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Xenetic on June 3, 2022 that its common stock bid price was below $1.00 for 30 consecutive business days.","Company has 180 calendar days (until November 30, 2022) to regain compliance with Nasdaq Listing Rule 5550(a)(2).","To cure, closing bid price must be at least $1.00 for a minimum of ten consecutive business days before the Compliance Date.","If not cured by Nov 30, Xenetic may be eligible for a second 180-day period if it meets other listing standards and notifies Nasdaq of intention to cure, possibly via reverse stock split.","There is no assurance the company will regain compliance; risk of delisting if deficiency is not addressed."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":370701,"accession_number":"0001683168-22-002961","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2022-04-27T23:59:59+00:00","items":["1.01","2.01","3.02","7.01","9.01"],"status":"ready","headline":"Xenetic Biosciences in-licenses DNase oncology platform from CLS Therapeutics for $500K cash + 875K shares + milestones","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Upfront payment: $500K cash + 875,000 common shares (250,000 issued to OPKO per third-party obligation).","Milestone payments up to $13M per program in cash plus up to 950,000 additional shares for regulatory milestones.","Licensed platform includes systemic DNase (co-admin with chemo/IO) and DNase-armored CAR T therapies.","Xenetic plans Phase 1 study of lead asset in locally advanced or metastatic solid tumors.","Tiered royalties on net sales (mid-single to low-double digits); sublicense revenue share in mid-teens to low-double digits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":389760,"accession_number":"0001683168-22-001853","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2022-03-23T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic reports FY2021 net loss of $5.6M; royalty revenue up 166% to $1.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss for FY2021 was approx $5.6M; R&D expenses rose to $3.2M (vs $1.7M in 2020) on XCART investment.","Cash at year-end $18.2M; working capital $17.3M, up from $11.4M in 2020.","Royalty payments from PolyXen platform totaled $1.2M, up 166% YoY, from Takeda sublicensee product launches.","XCART program advancing toward IND-enabling studies; U.S. patent for co-administration with personalized vaccine issued."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407720,"accession_number":"0001683168-21-006223","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2021-12-09T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Xenetic Biosciences stockholders approve director election, auditor ratification, equity plan increase","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["All seven director nominees elected; broker non-votes of 4,463,160 for each.","Ratification of Marcum LLP as independent auditor for FY2021 approved: 7,554,719 for, 106,532 against.","Advisory 'say-on-pay' resolution passed: 2,690,613 for, 472,665 against, 106,883 abstentions.","Amendment to Equity Incentive Plan to increase authorized shares by 1,500,000 approved: 2,568,737 for, 670,987 against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.15,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407719,"accession_number":"0001683168-21-005860","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2021-11-19T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Xenetic Biosciences enters $4M ATM equity offering with H.C. Wainwright","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered ATM Agreement with H.C. Wainwright as exclusive agent to sell up to $4M of common stock.","Shares sold at-the-market on Nasdaq; Wainwright receives 3% commission on gross proceeds.","Company has no obligation to sell any shares and may suspend or terminate the agreement.","Agreement effective November 19, 2021; filed as Exhibit 1.1 to the 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407718,"accession_number":"0001683168-21-005746","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2021-11-16T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Xenetic Biosciences exchanges 129,084 warrants for 51,634 common shares; amends 2019 Purchase Agreement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Warrants to purchase 129,084 shares exchanged for 51,634 common shares (0.4 ratio); all warrants cancelled.","Section 4.12(b) of the 2019 Securities Purchase Agreement deleted as part of the amendment.","No cash or other securities involved; exchange treated as cashless exercise under Section 3(a)(9).","Company agreed to standstill from Nov 15-19, 2021, not to issue shares or file registration statements."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407717,"accession_number":"0001683168-21-005470","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2021-11-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences reports Q3 net loss of ~$1.4M; cash $19.7M after $12.5M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss ~$1.4M for Q3 2021; R&D expenses up 36.1% to $0.8M, G&A up 17.5% to $0.9M.","Ended Q3 with cash ~$19.7M and working capital ~$19.5M after July $12.5M private placement.","XCART platform progressing toward IND-enabling studies; issued US patent for co-administration with personalized vaccine.","PolyXen royalty income ~$0.3M from Takeda sublicense in Q3; partner Pharmsynthez filed Epolong registration in Russia."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.41,"consensus_revenue_estimate":null,"consensus_revenue_actual":828088.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":407716,"accession_number":"0001683168-21-004865","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2021-10-15T23:59:59+00:00","items":["1.01","1.02"],"status":"ready","headline":"Xenetic Biosciences amends Pharmsynthez agreement; terminates prior work order, enters new one with $40K payment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Entered Amendment Number One to Master Service Agreement to terminate the prior Work Order with Pharmsynthez.","Executed a new Second Work Order for XCART technology development services upon written request.","Made a one-time $40,000 payment: $21,000 settles prior obligations, $19,000 creditable against future costs.","No further services under prior Work Order; all future work requires new work orders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426749,"accession_number":"0001683168-21-004238","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2021-09-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Xenetic Biosciences releases updated corporate presentation highlighting XCART CAR T program and upcoming milestones","summary_kind":"llm","event_type":"other_material","confidence":"medium","bullets":["XCART targets tumor-specific antigens independent of CD19, advancing toward a Phase 1 study.","Cash runway expected to fund the company through an IND filing for XCART.","Corporate presentation cites potential for increased efficacy, safety, and tolerability over approved CAR T therapies.","Expects CAR T therapies to hold significant revenue share by 2026 with a drop in Rituxan use.","Plans to leverage outsourced relationships and academic collaborations for clinical development."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426748,"accession_number":"0001683168-21-003522","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2021-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Xenetic Biosciences reports Q2 2021 net loss of $1.1M; completes $12.5M private placement","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Net loss $1.1M for Q2 2021; cash $9.3M at quarter end.","R&D expenses rose 70.4% to $0.5M, driven by XCART spending.","Received ~$0.3M in royalty payments from Takeda sublicense in Q2.","Completed $12.5M private placement in August 2021, net proceeds ~$11.4M.","Advancing XCART personalized CAR T platform toward IND-enabling studies."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":478819.0,"consensus_period":"2022-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426747,"accession_number":"0001683168-21-003133","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2021-07-28T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Xenetic Biosciences closes $12.5M private placement priced at $2.70/share; issues warrants with $3.30 strike","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Closed private placement of 4,629,630 shares at $2.70 per share for gross proceeds of $12.5M; H.C. Wainwright as placement agent.","Issued warrants to purchase up to 4,629,630 shares at $3.30, exercisable immediately; potential cash proceeds of $15.3M if fully exercised.","Pricing at a premium to market under Nasdaq rules; securities sold to a single healthcare-focused institutional investor.","Company intends net proceeds for general working capital purposes; agreement to file resale registration statement within 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":426746,"accession_number":"0001683168-21-002995","cik":1534525,"company_name":"Xenetic Biosciences, Inc.","ticker":"XBIO","form_type":"8-K","filed_at":"2021-07-16T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Director Dmitry Genkin resigns from Xenetic Biosciences board","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Dmitry Genkin resigned from the Board of Directors on July 15, 2021.","Resignation was not due to any disagreement with the Company.","No replacement director has been announced."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":6640000.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}